Germ Cell Tumor Molecular Heterogeneity Revealed through Analysis of Primary and Metastasis Pairs
Demographics (3)
- Age at Diagnosis - Age at Diagnosis (Years) (phv00435889.v1.p1)
- Gender - Gender (phv00435888.v1.p1)
- SEX - Biological sex (phv00435882.v1.p1)
Disease Events (1)
- DOD (Died of disease) - Whether patient Died of Disease (phv00492448.v1.p1)
Medications (3)
- Chemo resistant - Whether patient had chemotherapy resistant disease (phv00482786.v1.p1)
- First-line chemo regimen - First-line chemotherapy regimen (phv00435901.v1.p1)
- Salvage chemo - Whether patient had salvage chemotherapy (phv00435910.v1.p1)
Race and Ethnicity (1)
- Race - Race (phv00435887.v1.p1)
Other (40)
- AJCC 7 Stage - AJCC 7 Stage at presentation (phv00435894.v1.p1)
- ANALYTE_TYPE - Analyte Type (phv00435922.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00435921.v1.p1)
- Chemo Regimen Category - Firstline Chemotherapy Regimen Category (main chemotherapy regimen if various regimens given) (phv00435904.v1.p1)
- cM Stage - Clinical M (Mets) Stage (phv00435896.v1.p1)
- cN Stage - Clinical N (Nodes) Stage (phv00435895.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00435881.v1.p1)
- Disease Status at Last Follow up - Disease status at last Follow Up (phv00492450.v1.p1)
- Follow up Time from Diagnosis - Follow up Time from Diagnosis Date (phv00435914.v1.p1)
- Histological Type - Cell or tissue type or subtype of sample (phv00492451.v1.p1)
- IGCCCG Risk Group - IGCCCG ( International Germ Cell Cancer Collaborative Group) Risk Group (phv00435893.v1.p1)
- IS_TUMOR - Tumor status (phv00435923.v1.p1)
- Metastatic Site Location - Anatomical location of paired metastatic sample (phv00492453.v1.p1)
- MSK Historical Sample IDs - MSKCC additional sample-level identifier (historical) (phv00482793.v1.p1)
- MSK Patient IDs - MSKCC additional subject-level identifier (phv00482791.v1.p1)
- MSK Sample IDs - MSKCC additional sample-level identifier (phv00482792.v1.p1)
- MSK Subject ID - MSK internal subject ID (phv00435886.v1.p1)
- Number of cycles - Number of cycles of firstline chemotherapy (phv00435902.v1.p1)
- Overall Patient Histology - Overall Patient Histology (phv00435892.v1.p1)
- PC-RPLND - Whether patient had Post-chemotherapy RPLND (Retroperitoneal Lymph Node Dissection) (phv00435907.v1.p1)
- PC-RPLND pathology - Post-Chemo RPLND (Retroperitoneal Lymph Node Dissection) pathology results (phv00435909.v1.p1)
- POD after 1st line chemo - Whether patient had POD (Progression of Disease) as of data cutoff date (phv00492446.v1.p1)
- Primary or Metastatic Tumor - Whether sample is primary tumor or site of metastasis (phv00492452.v1.p1)
- Primary Tumor Histology - Primary Tumor Histology (phv00435899.v1.p1)
- Primary tumor site - Primary tumor site (phv00435890.v1.p1)
- pT Stage - PT Stage (phv00435898.v1.p1)
- S stage - S (Serum Tumor Marker) Stage (phv00435897.v1.p1)
- SAMPLE_ID - Sample ID (phv00435920.v1.p1)
- SAMPLE_ID - Sample ID (phv00435884.v1.p1)
- SUBJECT_ID - Subject ID (phv00435885.v1.p1)
- SUBJECT_ID - Subject ID (phv00435880.v1.p1)
- SUBJECT_ID - Subject ID (phv00435883.v1.p1)
- Teratoma in the Primary tumor - Was Teratoma in the Primary tumor (phv00435891.v1.p1)
- Time from Diagnosis to Firstline Chemotherapy - Time from Diagnosis to Chemotherapy (Days) (phv00482789.v1.p1)
- Time from Diagnosis to POD - Time from Diagnosis to POD (Progression of Disease) (phv00435918.v1.p1)
- Time from Firstline Chemo Start to POD (Progression of disease) - Time to POD (Progression of Disease, months from firstline chemo start) (phv00492447.v1.p1)
- Time from Start of Firstline Chemo to last follow up or death - Follow up Time from Start of Firstline Chemotherapy (phv00492449.v1.p1)
- Timing of specimen - Whether specimen was collected pre or post-firstline chemotherapy (phv00482790.v1.p1)
- Treated with chemotherapy - Whether or not patient was treated with Chemotherapy (phv00435900.v1.p1)
- Tumor Stage - Tumor Stage (phv00435928.v1.p1)